$APOG

Apogee (APOG) Q1 2027 Earnings Call Transcript

Apogee’s Q1 FY2027 earnings call said net sales fell 1.1% to $343M as lower metals and glass volume was partly offset by pricing and mix. Adjusted EBITDA margin fell to 9.4% (from 9.9%); adjusted diluted EPS rose to $0.57. Backlog ended at $735M (+8% YoY). The company cited rising input costs, pricing actions, and softer glass conditions, and reiterated full-year guidance of $1.38B–$1.43B net sales and $2.70–$3.25 adjusted EPS. Apogee expects Kalwall acquisition revenue of ~$85M at ~15% adjusted

Original reporting
Published Jun 27, 2026, 1:15 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 27, 2026, 1:54 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Apogee (APOG) Q1 2027 Earnings Call Transcript — source image
Decision brief

The 30-second read

$APOGBullishMed
01

Why it matters

The call provides concrete FY27 net sales and adjusted EPS ranges plus Kalwall close timing (early July) and expected first-12-month revenue/margins, which can reprice near-term earnings power and M&A/integration expectations. It also reiterates margin pressure from rising input costs and softer glass conditions, partially offset by pricing actions and cost savings (Fortify Phase 2).

02

Market read

Traders can update models for FY27 EPS/sales ranges and incorporate Kalwall’s expected contribution and integration timeline, while monitoring margin sensitivity to input costs and glass demand softness.

03

What to watch

Operating cash flow fell sharply vs prior year ($7.4M vs $19.8M), and services margin dynamics depend on project mix and tariff-related benefits that may not persist uniformly into the second half.

Relevance 7/10Novelty 6/10Timing: ahead of fiscal 2027 execution and early-July Kalwall close

Background

Apogee’s Q1 2027 earnings call updates segment performance (metals, services, glass, performance surfaces), cash flow/capital allocation, and provides FY27 guidance alongside the Kalwall acquisition update.

Company-level read

Ticker impact

$APOGBullishMedium confidence
Context

Apogee guided FY27 adjusted EPS to $2.70–$3.25 and said Kalwall acquisition should close in early July and be accretive in year one.

Expected impact

Likely supportive for the stock on guidance/accetiveness, but volatility possible around margin headwinds (input costs, glass softness) and integration execution.

Evidence & confidence

The text provides explicit FY27 sales/EPS ranges plus Kalwall revenue/margin assumptions and timing (early July close), which are actionable for positioning; however, it lacks consensus/market reaction context and detailed deal price/financing.

Market effects

Signals continued demand softness in glass/new construction while services and performance surfaces show resilience, informing read-across for building-envelope and fenestration suppliers.

No specific regional demand or policy details provided; impact appears driven by end-market conditions and input-cost dynamics.

No direct global macro/regulatory triggers cited beyond tariffs/project Fortify actions and material/freight cost recovery.

Counterpoint

Kalwall’s assumed accretion and margin profile may be optimistic versus ongoing glass/new-construction softness and input-cost volatility; integration execution could dilute benefits.

Key entities

  • Apogee

    US building products company reporting Q1 results, FY27 guidance, and Kalwall acquisition details.

  • Kalwall

    Building envelope/daylighting solutions acquisition expected to close in early July and be accretive in year one.

Related articles

$APOGMedAI 8/10

Apogee to buy Luca Mariano Distillery for $19.5m

Apogee 21 (A21 Wine & Spirits) says it was selected as the successful bidder in a Chapter 11 court sale to buy Luca Mariano Distillery for $19.5m, including a 529-acre campus, assets, and about 6,600 ageing Bourbon barrels. The company plans to fund the purchase via $7m from investors, senior secured debt, and other financing, plus a $20m Series D. It also signed an LOI to buy Rod & Hammer’s whiskey brand and distillery in California.

$APOGMed

APOGEE ENTERPRISES, INC. (APOG): Completion of Acquisition or Disposition of Assets

APOGEE ENTERPRISES, INC. (APOG) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. apog-20260701 0000006845 false 0000006845 2024-11-04 2024-11-04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported):

$APOGMedAI 8/10

Why Is Apogee Enterprises Stock Soaring Friday? - Apogee Enterprises (NASDAQ:APOG)

Apogee Enterprises reported Q1 adjusted diluted EPS of 57 cents, above the 45-cent consensus, on net sales of $342.7 million versus $333.8 million expected. The company cited pricing/product mix for offsetting a 1.1% volume decline. Operating income rose to $18.8 million; operating margin to 5.5%. It kept fiscal 2027 adjusted EPS guidance of $2.70–$3.25 and sales outlook of $1.38–$1.43 billion; Kalwall acquisition remains on track for early July. Shares were up 9.44% to $46.49.

$APOGMed

APOGEE ENTERPRISES, INC. (APOG): Results of Operations and Financial Condition

APOGEE ENTERPRISES, INC. (APOG) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a53026fy27q1results.htm EX-99.1 Document Press Release FOR RELEASE: June 26, 2026 APOGEE ENTERPRISES REPORTS FISCAL 2027 FIRST QUARTER RESULTS • First-quarter net sales of $342.7 million • First-quarter diluted EPS of $0.54 and adjusted diluted EPS of $0.57 • Pending Ka

$GOOGMed

Dow Jones still in the green but Nasdaq drops as hawkish Fed still looms

US stocks opened with the Dow up about 0.5% and the S&P 500 up just over 0.3%, while the Nasdaq was flat as investors took profits in tech. Alphabet fell 5.5% after losing AI researcher Noam Shazeer to OpenAI. AbbVie agreed to buy Apogee for ~$10.9B cash ($135.11/share). Oil eased as traders expected US-Iran supply disruptions to lessen; core PCE and Micron earnings are key this week.